The use of glucocorticoids in marmoset wasting syndrome
BackgroundMarmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation.
MethodEleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8weeks.
ResultsThe marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy.
ConclusionsGlucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.
Otovic, P., Smith, S., & Hutchinson, E. (2015). The use of glucocorticoids in marmoset wasting syndrome. Journal of Medical Primatology, 44(2), 53-59. https://doi.org/10.1111/jmp.12159